NCT06473948View on ClinicalTrials.gov

To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

September 24, 2024

Study Completion Date

February 27, 2025

Conditions
Solid Tumor, Adult
Interventions
DRUG

JMKX001899

Participants will receive JMKX001899 500mg tablet, orally once on Day 1

DRUG

JMKX001899

Participants will receive JMKX001899 750mg tablet, orally once on Day 1

DRUG

JMKX001899

Participants will receive JMKX001899 1000mg tablet, orally once on Day 1

DRUG

Placebo

Participants will receive JMKX001899 matching placebo, tablet, orally once on Day 1

Sponsors

Lead Sponsor

Jemincare
All Listed Sponsors
lead

Jemincare

INDUSTRY

NCT06473948 - To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects | Biotech Hunter | Biotech Hunter